Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ineligible patients with multiple myeloma, comparing melphalan-prednisolone in co...

Descripción completa

Detalles Bibliográficos
Autores principales: Nielsen, Lene Kongsgaard, Stege, Claudia, Lissenberg-Witte, Birgit, van der Holt, Bronno, Mellqvist, Ulf-Henrik, Salomo, Morten, Bos, Gerard, Levin, Mark-David, Visser-Wisselaar, Heleen, Hansson, Markus, van der Velden, Annette, Deenik, Wendy, Coenen, Juleon, Hinge, Maja, Klein, Saskia, Tanis, Bea, Szatkowski, Damian, Brouwer, Rolf, Westerman, Matthijs, Leys, Rineke, Sinnige, Harm, Haukås, Einar, van der Hem, Klaas, Durian, Marc, Gimsing, Peter, van de Donk, Niels, Sonneveld, Pieter, Waage, Anders, Abildgaard, Niels, Zweegman, Sonja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271593/
https://www.ncbi.nlm.nih.gov/pubmed/31515355
http://dx.doi.org/10.3324/haematol.2019.222299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271593/
https://www.ncbi.nlm.nih.gov/pubmed/31515355
http://dx.doi.org/10.3324/haematol.2019.222299

Ejemplares similares